Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Documenti analoghi

• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
  di: Glatt, Sophie, et al.
  Pubblicazione: (2018)
• Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells
  di: Shah, Mittal, et al.
  Pubblicazione: (2020)
• Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling
  di: Cole, Suzanne, et al.
  Pubblicazione: (2020)
• First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
  di: Glatt, Sophie, et al.
  Pubblicazione: (2017)
• Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
  di: Shaw, Stevan, et al.
  Pubblicazione: (2014)